Nyxoah Signs Memorandum of Understanding with Sheikh Shakhbout Medical City
Nyxoah has announced the signing of a memorandum of understanding with Sheikh Shakhbout Medical City (SSMC), a hospital in the United Arab Emirates specializing in complex and serious care. This agreement aims to strengthen Nyxoah's presence in the Middle East and to expand access to its Genio® therapy.
The memorandum of understanding was signed between Nyxoah SA and Sheikh Shakhbout Medical City, a subsidiary of PureHealth, the largest healthcare group in the Middle East. The agreement reflects Nyxoah's strategic orientation to collaborate with regional medical centers of excellence to expand access to its Genio® hypoglossal nerve stimulation (HGNS) therapy, while supporting the highest standards in clinical care, education, and scientific collaboration.
Establishing a Regional Hub
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Nyxoah and SSMC are committed to positioning SSMC as a leading regional center for Genio therapy, supporting the development of a high-volume implantation program focused on patient-centered care. The collaboration also plans to establish SSMC as a regional training center for Genio therapy in the Middle East, aimed at supporting the training of surgeons, sleep specialists, and healthcare professionals in the region. Both parties are also exploring discussions related to clinical research and collaboration in the field of sleep apnea and the management of chronic and metabolic diseases.
Regulatory Milestones
The Genio® system received CE marking in 2019. FDA approval was obtained in August 2025 for a subgroup of adult patients suffering from moderate to severe obstructive sleep apnea with an apnea-hypopnea index greater than or equal to 15 and less than or equal to 65. The system also received CE marking for the extension of its therapeutic indications to patients with complete concentric collapse.
Related
SectorDispositifs médicaux et optique›Dispositifs médicaux
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: T3 2026
Key reported figures
Revenue: 9,2 millions d'euros
Quarterly revenue: 9,2 millions d'euros
Revenue growth: 366,5 %
Guidance from the release
Bien que nous soyons déçus d'ajuster nos prévisions de chiffre d'affaires
Risks mentioned
Ajustement à la baisse des prévisions de chiffre d'affaires (de 36-40 M€ à 33-35 M€)
Trajectoire de croissance inférieure aux attentes pour l'exercice 2026
Dépendance à la ramp-up des États-Unis reflétant les cycles historiques d'une nouvelle technologie
Opportunities identified
Supplément PMA soumis à la FDA pour étendre l'indication américaine aux patients atteints de collapsus concentrique complet
Croissance séquentielle de 29 % du chiffre d'affaires aux États-Unis au T3 2026
Expansion du nombre de chirurgiens formés (342 cumulés) et comptes activés (233 à fort volume) aux États-Unis
Outlook / guidance
Expected revenue: 34 millions d'euros
Management commentary: The Company now expects global net revenue for the full year 2026 to be in the range of €33 million to €35 million, compared to €36 million to €40 million previously.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
